Gastrointestinal Drugs Market Scope And Analysis

Report Code : TIPRE00014758
Category : Pharmaceuticals

Status : Published
No. of Pages : 211

Buy Now

Gastrointestinal Drugs Market Scope and Analysis Report by 2027

Buy Now

Gastrointestinal Drugs Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 59,713.68 Million
Market Size by 2031	US$ 106,304.81 Million
Global CAGR (2023 - 2031)	7.5%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Drug Class Biologics Antidiarrheal and Laxatives Acid Neutralizers Anti-inflammatory Drugs Antiemetic and Antinauseants By Application Irritable Bowel Syndrome Inflammatory Ulcerative Colitis Crohns Disease Gastroenteritis Celiac Disease By Route Of Administration Oral and Parenteral By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Sanofi SA GSK Plc Johnson Johnson Bausch Health Companies Inc AstraZeneca Pl Takeda Pharmaceutical Co Ltd AbbVie Inc Bayer AG Pfizer Inc Celltrion Inc

Gastrointestinal Drugs Market News and Recent Developments

The gastrointestinal drugs market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the gastrointestinal drugs market are listed below:

Bayer Consumer Health introduced Iberogast, a plant-based digestive relief product, to millions of people in the US who experience gut health issues. Formulated with a clinically proven, proprietary six-herb blend, Iberogast harnesses the power of nature to provide dual-action relief for those who experience occasional digestive symptoms by helping to relieve stomach upsets and restore digestive function. (Source: Bayer AG, Press Release, April 2024)
AbbVie Inc. and Landos Biopharma, Inc. entered into a definitive agreement under which AbbVie acquired Landos, a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist with a bimodal mechanism of action, which is anti-inflammatory and facilitates epithelial repair. (Source: AbbVie Inc., Press Release, March 2024)

Gastrointestinal Drugs Market Report Coverage and Deliverables

The “Gastrointestinal Drugs Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Gastrointestinal drugs market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Gastrointestinal drugs market trends as well as market dynamics such as drivers, restraints, and key opportunities
Detailed PEST and SWOT analysis
Gastrointestinal drugs market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the gastrointestinal drugs market
Detailed company profiles